CLL

WellBe, a new voice-enabled virtual assistant, can remind patients with cancer to take their medication and keep them on track from the comfort of their own home.
 

Dr. Othman Al-Sawaf discusses the encouraging long-term data that makes the Venclexta-Gazyva combination a viable treatment option for patients with CLL.
 

“Final results from ASCEND confirm the findings of the interim analysis and support the favorable efficacy and safety of (Calquence) versus standard-of-care regimens in relapsed or refractory CLL,” said Dr. Paolo Ghia.
 

A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa.
 

A list of the recent trial initiations that occurred within the cancer space in July.
 

A three-drug treatment sparked complete responses in more than half of patients with high-risk chronic lymphocytic leukemia, who also tolerated the regimen well.
 

“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE^®.
 

“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”
 

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.
 

In an interview with CURE®, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.